Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

Wu, TC; Stube, A; Felix, C; Oseguera, D; Romero, T; Goldman, J; Garon, EB; Lee, JM; Glaspy, J; Lisberg, AE; Rusthoven, CG; Camidge, DR; Siva, S; Solomon, B; Lee, A; Tenn, SE; Shaverdian, N; Steinberg, ML; Raldow, AC; Lee, P

Author(s): Wu, TC; Stube, A; Felix, C; Oseguera, D; Romero, T; Goldman, J; Garon, EB; Lee, JM; Glaspy, J; Lisberg, AE; Rusthoven, CG; Camidge, DR; Siva, S; Solomon, B; Lee, A; Tenn, SE; Shaverdian, N; Steinberg, ML; Raldow, AC; Lee, P;
Details: Publication Year 2023-09-01,Volume 117,Issue #1,Page 118-122
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Publication Type: Research article
Publisher: Elsevier
Keywords: Humans; *Carcinoma, Non-Small-Cell Lung/radiotherapy; *Lung Neoplasms/therapy; Antibodies, Monoclonal/adverse effects; *Radiosurgery/adverse effects
Department(s): Radiation Oncology; Medical Oncology
PubMed ID: 37023987
Publisher's Version: https://doi.org/10.1016/j.ijrobp.2023.03.069
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-11-21 05:54:44

Last Modified: 2024-07-30 01:56:11